Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Acute myeloid leukemia |
1件: RARA | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
2 | Adipocytokine signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
3 | African trypanosomiasis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
4 | AGE-RAGE signaling pathway in diabetic complications |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
5 | Allograft rejection |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
6 | Alzheimer disease |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
7 | Amoebiasis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
8 | Amphetamine addiction |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
9 | AMPK signaling pathway |
1件: HMGCR | D00887 | Atorvastatin | 17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
D07474 | |||||
D00359 | Lovastatin | 10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 | |||
10 | Amyotrophic lateral sclerosis (ALS) |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
11 | Antifolate resistance |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
12 | Antigen processing and presentation |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
13 | Apoptosis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
14 | Arachidonic acid metabolism |
1件: ALOX5 | D00414 | Zileuton | 3件: 85, 160, 164 |
15 | Asthma |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
16 | Axon guidance |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
17 | B cell receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
18 | Bile secretion |
1件: HMGCR | D00887 | Atorvastatin | 17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
D07474 | |||||
D00359 | Lovastatin | 10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 | |||
19 | C-type lectin receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
20 | Calcium signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
21 | cAMP signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
22 | Cellular senescence |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
23 | cGMP-PKG signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
24 | Chagas disease (American trypanosomiasis) |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
25 | Cytokine-cytokine receptor interaction |
1件: IL17A | D09967 | Secukinumab | 7件: 13, 37, 41, 46, 160, 269, 271 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
26 | Dilated cardiomyopathy (DCM) |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
27 | Dopaminergic synapse |
3件: PPP3CA, PPP3CB, PPP3CC | D05480 | Pimecrolimus | 1件: 160 |
28 | Epstein-Barr virus infection |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
29 | Estrogen signaling pathway |
1件: RARA | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
30 | Fc epsilon RI signaling pathway |
1件: ALOX5 | D00414 | Zileuton | 3件: 85, 160, 164 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
31 | Fluid shear stress and atherosclerosis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
32 | Gastric cancer |
1件: RARB | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
33 | Glucagon signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 | ||
34 | Glutamatergic synapse |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
35 | Graft-versus-host disease |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
36 | Hematopoietic cell lineage |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
37 | Hepatitis B |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
38 | Hepatitis C |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
39 | Herpes simplex virus 1 infection |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
40 | Human cytomegalovirus infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
41 | Human immunodeficiency virus 1 infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
42 | Human papillomavirus infection |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
43 | Human T-cell leukemia virus 1 infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
44 | Hypertrophic cardiomyopathy (HCM) |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
45 | IL-17 signaling pathway |
1件: IL17A | D09967 | Secukinumab | 7件: 13, 37, 41, 46, 160, 269, 271 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
46 | Inflammatory bowel disease (IBD) |
1件: IL17A | D09967 | Secukinumab | 7件: 13, 37, 41, 46, 160, 269, 271 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
47 | Influenza A |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
48 | Insulin resistance |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
49 | Kaposi sarcoma-associated herpesvirus infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
50 | Legionellosis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
51 | Leishmaniasis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
52 | Long-term potentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
53 | Malaria |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
54 | MAPK signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
55 | Metabolic pathways |
1件: ALOX5 | D00414 | Zileuton | 3件: 85, 160, 164 |
1件: HMGCR | D00887 | Atorvastatin | 17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 | ||
D07474 | |||||
D00359 | Lovastatin | 10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 | |||
56 | mTOR signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
57 | Natural killer cell mediated cytotoxicity |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
58 | Necroptosis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
59 | NF-kappa B signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
60 | NOD-like receptor signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
61 | Non-alcoholic fatty liver disease (NAFLD) |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
62 | Non-small cell lung cancer |
1件: RARB | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
63 | Oocyte meiosis |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
64 | Osteoclast differentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
65 | Ovarian steroidogenesis |
1件: ALOX5 | D00414 | Zileuton | 3件: 85, 160, 164 |
66 | Oxytocin signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
67 | Pathogenic Escherichia coli infection |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
68 | Pathways in cancer |
2件: RARA, RARB | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
69 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
70 | Pertussis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
71 | PPAR signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
72 | Proteoglycans in cancer |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
73 | Renin secretion |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
74 | Rheumatoid arthritis |
1件: IL17A | D09967 | Secukinumab | 7件: 13, 37, 41, 46, 160, 269, 271 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
75 | RIG-I-like receptor signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
76 | Serotonergic synapse |
1件: ALOX5 | D00414 | Zileuton | 3件: 85, 160, 164 |
77 | Shigellosis |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
78 | Small cell lung cancer |
1件: RARB | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
79 | Sphingolipid signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
80 | Systemic lupus erythematosus |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
81 | T cell receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
82 | Terpenoid backbone biosynthesis |
1件: HMGCR | D00887 | Atorvastatin | 17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
D07474 | |||||
D00359 | Lovastatin | 10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 | |||
83 | TGF-beta signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
84 | Th1 and Th2 cell differentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
85 | Th17 cell differentiation |
1件: IL17A | D09967 | Secukinumab | 7件: 13, 37, 41, 46, 160, 269, 271 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 | ||
1件: RARA | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 | ||
86 | TNF signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
87 | Toll-like receptor signaling pathway |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
88 | Toxoplasmosis |
1件: ALOX5 | D00414 | Zileuton | 3件: 85, 160, 164 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
89 | Transcriptional misregulation in cancer |
1件: RARA | D00348 | Isotretinoin | 4件: 36, 39, 159, 160 |
90 | Tuberculosis |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 | ||
91 | Type I diabetes mellitus |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
92 | Type II diabetes mellitus |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
93 | VEGF signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
94 | Viral protein interaction with cytokine and cytokine receptor |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
95 | Wnt signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D05480 | Pimecrolimus | 1件: 160 |
96 | Yersinia infection |
1件: TNF | D02597 | Adalimumab | 15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |